Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy | Zendy

Yoshifumi Kadono | Zendy; Takahiro Nohara | Zendy; Satoru Ueno | Zendy; Kouji Izumi | Zendy; Yasuhide Kitagawa | Zendy; Hiroyuki Konaka | Zendy; Atsushi Mizokami | Zendy; Mizuki Onozawa | Zendy; Shiro Hinotsu | Zendy; Hideyuki Akaza | Zendy; Mikio Namiki | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy

Author(s) -

Yoshifumi Kadono,

Takahiro Nohara,

Satoru Ueno,

Kouji Izumi,

Yasuhide Kitagawa,

Hiroyuki Konaka,

Atsushi Mizokami,

Mizuki Onozawa,

Shiro Hinotsu,

Hideyuki Akaza,

Mikio Namiki

Publication year - 2015

Publication title -

world journal of urology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.552

H-Index - 83

eISSN - 1433-8726

pISSN - 0724-4983

DOI - 10.1007/s00345-015-1607-3

Subject(s) - medicine , prostate cancer , androgen deprivation therapy , oncology , proportional hazards model , bone metastasis , metastasis , stage (stratigraphy) , prostate specific antigen , lymph node , prostate , cancer , paleontology , biology

The current tumor-node-metastasis (TNM) classification system has been used for many years. The prognosis of patients with metastatic prostate cancer (mPC) treated using primary androgen deprivation therapy (PADT) was analyzed according to the TNM classification.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research